Presentation is loading. Please wait.

Presentation is loading. Please wait.

Competitive TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) Following Allogeneic Stem Cell Transplantation (SCT).

Similar presentations


Presentation on theme: "Competitive TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) Following Allogeneic Stem Cell Transplantation (SCT)."— Presentation transcript:

1 Competitive TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) Following Allogeneic Stem Cell Transplantation (SCT). A Joint Pediatric Blood and Marrow Transplant Consortium (PBMTC) and Childrens Oncology Group (COG) Study  Gregory Yanik, Stephan Grupp, Michael A. Pulsipher, John E. Levine, Kirk R. Schultz, Donna A. Wall, Bryan Langholz, Christopher C. Dvorak, Keith Alangaden, Kenneth R. Cooke  Biology of Blood and Marrow Transplantation  Volume 19, Issue 2, Pages S111-S112 (February 2013) DOI: /j.bbmt Copyright © Terms and Conditions

2 Biology of Blood and Marrow Transplantation 2013 19, S111-S112DOI: (10
Biology of Blood and Marrow Transplantation  , S111-S112DOI: ( /j.bbmt ) Copyright © Terms and Conditions


Download ppt "Competitive TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) Following Allogeneic Stem Cell Transplantation (SCT)."

Similar presentations


Ads by Google